2014-09-03 21:32:53 UTC

Gastroenterology Podcast September 2014: Vedolizumab for Crohn’s Patients After TNF Therapy Has Failed

A study in the September issue of Gastroenterology evaluated the effects of vedolizumab induction therapy for patients with Crohn’s disease for whom tumor necrosis factor (TNF) antagonists have already failed. Dr. Kuemmerle speaks with the first author of the study, Dr. Bruce E. Sands of the Ichan School of Medicine at Mount Sinai, New York; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

 

 

Sands BE, Feagan BG, Rutgeerts P, et al. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. Gastroenterology 2014; September; 147(3): 618–627.e3
Abstract

 

 

Duration: 16.54m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

More on Crohn's Disease

Leading patient, professional organizations announce funding to improve communications, address IBD shared decision-making

April 17, 2018

Funding recipients will address ways to improve shared decision-making and effective health communications.

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

The Development and Approval of Inflectra, a Biosimilar to Remicade: Case Presentation

April 3, 2018

In this on-demand webinar, Sue Lim, MD of the FDA provides a general review of the requirements for a biosimilar 351(k) application and discusses the approval process for Inflectra.